Navigation Links
Spring Bioscience launches highly sensitive PD-L1 (SP142) antibody for immunotherapy research
Date:8/25/2014

PLEASANTON, Calif., Aug. 25, 2014 /PRNewswire/ -- Spring Bioscience (Spring), a member of the Roche Group, today announced the launch of its PD-L1 (SP142) rabbit monoclonal immunohistochemistry (IHC) antibody1. This new PD-L1 clone was developed for Roche/Genentech's anti-PD-L1 (MPDL3280A) immunotherapy development program and included in research of various tumor types.

As pharmaceutical companies continue to research and develop cancer drugs that target the immune system, measuring the amount of PD-L1 protein expressed on tumor cells and tumor-infiltrating immune cells may help assess the efficacy and durability of investigational drugs that inhibit the binding of the PD-L1 protein.

Internal comparison studies performed at Spring demonstrated that the PD-L1 (SP142) antibody outperformed other commercially available PD-L1 antibodies. "As with all IHC antibodies developed by Spring, the SP142 antibody will deliver the high quality and accuracy that clinical researchers need to confidently assess PD-L1 status in tissue samples," said Michael Rivers, GM, Spring Biosience. 

"The development of the PD-L1 (SP142) antibody was designed to be very sensitive and specific. As researchers strive to understand the clinical relevance of PD-L1 expression, this clone may offer a superior ability to stain and analyze both tumor and immune cells," said Doug Ward, VP and Lifecycle Leader, Ventana Compaion Diagnostics. "Ventana and Spring are committed to delivering gold standard biomarker detection solutions for companion diagnostic tests."

Spring Bioscience is known across the research industry for its quality development practices and for delivering a consistent supply of highly-specific antibodies. SP142 meets the company's high standards as a valuable tool for assessing PD-L1 expression in many different tumor types.

Recommended staining protocols are available for manual, semi-automated and VENTANA Discovery platforms for decreased assay development times.

To order or request additional information on SP142, please visit springbio.com or call (800) 787-6896 or (925) 474-8440. Orders can also be submitted via e-mail at spring.orders@ventana.roche.com with technical detail available through spring.tech@ventana.roche.com.

1PD-L1 (SP142) Rabbit Monoclonal Antibody is for Research Use Only (RUO). Not for use in diagnostic procedures.

About Spring Bioscience
Spring Bioscience, Inc. (Spring) is a leading developer of rabbit monoclonal antibodies, engineered for immunohistochemistry (IHC) and other applications in tissue-based cancer research. Founded by scientists with a primary focus on IHC, Spring has developed a proprietary menu of highly-sensitive antibodies (SP clones) that yield superior specificity and consistency in research and clinical practice. Spring is committed to high-quality development standards and also offers a portfolio of advanced detection and other complementary products for reliable, reproducible assessments of protein expression. Spring Bioscience was acquired by Ventana Medical Systems, Inc., a member of the Roche Group, in 2007. As an antibody center of excellence for Roche with strong pharmaceutical partnerships across the industry, Spring is at the frontier of antibody development for companion diagnostics, IVD and early clinical markers. Learn more at Springbio.com.

About Ventana Medical Systems, Inc.
Ventana Medical Systems, Inc. ("VMSI") (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA products are used in clinical histology and drug development research laboratories worldwide. The company's intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to help reduce errors, support diagnosis and enable informed treatment decisions by anatomic pathology professionals. Together with Roche, VMSI is driving Personalized Healthcare through accelerated drug discovery and the development of "companion diagnostics" to identify the patients most likely to respond favorably to specific therapies.

VENTANA, the VENTANA logo, and DISCOVERY are trademarks of Roche.

VMSI Media Relations
Jacqueline Bucher
Senior Director, Corporate Communications
Ventana Medical Systems, Inc.
Tel 520.877.7288 o
Tel 520.468.9145 m
e-mail: Jacquie Bucher

Photo - http://photos.prnewswire.com/prnh/20140822/139008


'/>"/>
SOURCE Spring Bioscience
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardium Exhibiting Its New FDA-Cleared Excellagen® At The 2012 Spring Symposium Of Advanced Wound Care
2. Top buyers including Atico, Coles Group Asia, Kmart, Staples, Office Depot and Target Australia pre-registered to attend Global Sources spring China Sourcing Fairs
3. Neusoft Medical Launches NeuViz 64 Multi-slice CT Scanner at CMEF Spring 2012
4. Islet Sciences Announces Strategic Alliance with Spring Point Project
5. Spring Bank Pharmaceuticals Closes $10.5 million Series A Financing to fund Phase I Clinical Trials in HCV-infected Patients
6. SI-BONE, Inc. Announces Spring Society Meeting Attendance
7. Pressure BioSciences, Inc. to Present at the SeeThruEquity Spring Investor Microcap Forum
8. GlySure CEO to Present ICU Trial Results at Spring Medtech Industry Conferences
9. Spring Allergies Start Strong and Last Long As Extreme Weather Patterns Continue
10. Hurel Receives $9.2 Million Series A Funding From Spring Mountain Capital
11. Neusoft Medical Launches New Products to Global Market at 2013 Spring CMEF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , May 4, 2016  It,s time for an upgrade. There are many ... a brilliant 3.5 inch LCD, the illustrious DVMAXX HD  offers unparalleled connectivity and ... well as a world class manufacturer of innovative technology.  Photo - ... ... ...
(Date:5/4/2016)... , May 4, 2016 ... of Jerusalem announced today that it had signed ... BioTheryX, Inc. , developer of novel protein degradation and ... development and commercialization of drug candidates representing first-in-class therapy ... license were not disclosed. The novel technology ...
(Date:5/4/2016)... DUBLIN , May 4, 2016 /PRNewswire/ ... the addition of the  "Global Multiple Myeloma ...  report to their offering.       ... Multiple Myeloma Market and Competitive Landscape Highlights ... pipeline products, Multiple Myeloma epidemiology, Multiple Myeloma ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... If you don’t mind a bit of prickly ... may want to consider a treatment that some have called the next great tool ... , Microneedling, also known as skin needling, is a procedure using a device covered ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... Medical Society of Northern Virginia, Announces DoctorsTelemed?, A telehealth solution powered ... of Northern Virginia (MSNVA) launches DoctorsTelemed?, a telemedicine solution that uses CloudVisit’s ...
(Date:5/5/2016)... ... May 05, 2016 , ... Augusta Public Schools has teamed with ... partnership will enable school health offices to streamline and bolster care for district students. ... east of Wichita. Augusta public schools serve 2,300 students among its six schools. ...
(Date:5/5/2016)... ... 2016 , ... The Wisconsin Independent Private Practice Alliance (WIPPA/aka ... WCS, has been selected by the Wisconsin Physical Therapy Association (WPTA) as this ... is awarded annually to a member of the WPTA to recognize a Wisconsin ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... patented products, announces the Everlasting Glove, a sports invention that aids in the ... Sporting Goods Manufacturing industry is worth $9 billion," says Scott Cooper, CEO and ...
Breaking Medicine News(10 mins):